Related Experiment Video

Updated: Feb 12, 2026

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.7K

Interleukin-2 receptor antagonists: Protective factors against new-onset diabetes after renal transplantation

Mengjuan Xue1,2, Chenhe Zhao1, Chaoyang Lv1,3

  • 1Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.

Journal of Diabetes
|March 27, 2018
PubMed
Abstract

Insights

Interleukin-2 receptor antagonists (IL-2Ra) may reduce the risk of new-onset diabetes after transplantation (NODAT) in renal transplant recipients (RTRs). This study found IL-2Ra use was associated with a lower incidence of NODAT.

Area of Science:

  • Nephrology
  • Immunology
  • Endocrinology

Background:

  • New-onset diabetes after transplantation (NODAT) is a significant complication in renal transplant recipients (RTRs).
  • Interleukin-2 receptor antagonists (IL-2Ra) are used as immunosuppressants in RTRs, but their effect on NODAT is not fully understood.

Purpose of the Study:

  • To investigate the association between the use of IL-2Ra and the development of NODAT in RTRs.
  • To identify risk factors for NODAT in a cohort of RTRs.

Main Methods:

  • Retrospective cohort study of 557 RTRs from January 1993 to March 2014.
  • Multivariate Cox regression analysis to assess risk factors and the association between IL-2Ra and NODAT.
  • Comparison of cumulative NODAT incidence between groups with and without IL-2Ra treatment.

Main Results:

  • The incidence of NODAT was 20.3% over a mean follow-up of 5.08 years.
  • After adjusting for multiple confounders, IL-2Ra use was significantly associated with a reduced incidence of NODAT.
  • Confounders included age, BMI, diabetes history, dialysis details, donor type, graft function, rejection, infections, glucose levels, lipid profiles, and immunosuppression regimen.

Conclusions:

  • IL-2Ra use is linked to a protective effect against NODAT development in RTRs.
  • Further research may explore the mechanisms behind this protective association.
Keywords:
interleukin-2kidney transplantationnew-onset diabetes after transplantationreceptor antagonists受体拮抗剂白细胞介素2移植后新发糖尿病肾移植

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.2K
Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice10:43

Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice

Published on: October 31, 2007

28.9K

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
485
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.4K